A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo

• Published in: British journal of cancer 1982-12, Vol.46 (6), p.904-911
• Main Authors: Overgaard, J, Overgaard, M, Nielsen, O S, Pedersen, A Kirstein, Timothy, A R
• Format: Article
• Language: English
• Subjects: Animals; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cell Survival - drug effects; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance; Epidemiology; Female; Male; Mammary Neoplasms, Experimental - radiotherapy; Mice; Mice, Inbred Strains; Misonidazole - therapeutic use; Misonidazole - toxicity; Molecular Medicine; Nimorazole - therapeutic use; Nimorazole - toxicity; Nitroimidazoles - therapeutic use; Oncology; original-article; Oxygen; Radiation-Sensitizing Agents - therapeutic use
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.1982.300

The hypoxic cell radiosensitizing properties of nimorazole have been investigated in a C3H mammary carcinoma transplanted to the feet of C3D2F1. The results have been compared with those obtained with misonidazole (MISO) in the same animal tumour system. For single-dose irradiation in air, nimorazole gives an enhancement ratio (ER) of approximately 1.4, independent of the dose of drug administered over the range 0.1-1.0 mg/g. MISO yields a similar ER at the 0.1 mg/g level but, unlike nimorazole, shows a steep dose-response curve with an ER of 2.2 when given in a concentration of 1.0 mg/g. No such dose-response relationship is seen with nimorazole despite the fact that tumour and plasma concentrations of the 2 drugs have an identical dose relationship. With irradiation given in 5 daily fractions, nimorazole and MISO at a dose of 0.3 mg/g per fraction both show an ER of approximately 1.3. The high drug doses used in single-fraction radiation experiments in animals bear little relation to those applicable to clinical practice since these would result in unacceptable toxicity. The results of the present studies are therefore of interest as nimorazole is potentially less toxic than MISO in humans but demonstrates similar radiosensitizing properties at clinically relevant dose levels.